Zheng Yan

US Patent:

8063225, Nov 22, 2011

Filed:

Aug 10, 2007

Appl. No.:

11/891604

Inventors:

Vlad E. Gregor - Del Mar CA, US
Yahua Liu - San Diego CA, US
Alexey Anikin - Ivanteevka, RU
Danny Peter Claude McGee - Vista CA, US
Charles Mikel - Escondido CA, US
Douglas Eric McGrath - San Marcos CA, US
Goverdhan Reddy Vavilala - San Marcos CA, US
Jason C. Pickens - San Diego CA, US
Alexander Kadushkin - Zheleznodorozhnyi, RU
Luyong Jiang - San Marcos CA, US
Mohan Santhanam Thiruvazhi - San Diego CA, US
Sergey Zozulya - San Diego CA, US
Rajendran Vairagoundar - San Marcos CA, US
Tong Zhu - San Diego CA, US
Alexander Chucholowski - San Diego CA, US
Thomas Webb - Millington TN, US
Vidyasagar Reddy Gantla - San Diego CA, US
Zheng Yan - San Diego CA, US

Assignee:

Chembridge Corporation - San Diego CA

International Classification:

C07D 401/00
A61K 31/44

US Classification:

5462731, 514338

Abstract:

Provided are compounds of the formula (I):.

US Patent:

8629147, Jan 14, 2014

Filed:

Nov 2, 2006

Appl. No.:

11/593191

Inventors:

Alexey Vyacheslavovich Anikin - San Diego CA, US
Vidyasagar Reddy Gantla - San Diego CA, US
Vlad Edward Gregor - Del Mar CA, US
Luyong Jiang - San Marcos CA, US
Yahua Liu - San Diego CA, US
Danny Peter Claude McGee - Vista CA, US
Charles Chamchoumis Mikel - Escondido CA, US
Jason Conrad Pickens - San Diego CA, US
Thomas Roy Webb - Millington TN, US
Zheng Yan - San Diego CA, US
Tong Zhu - San Diego CA, US
Aleksander Kadushkin - Zheleznodorozhnyi, RU
Sergey Sviridov - Moscow, RU
Sergey Zozulya - San Diego CA, US
Alexander Chucholowski - San Diego CA, US
Douglas Eric McGrath - San Marcos CA, US

Assignee:

ChemBridge Corporation - San Diego CA

International Classification:

A61K 31/497
A61K 31/47
A61K 31/445

US Classification:

51425309, 514314, 514318, 514338

Abstract:

The present invention provides compounds capable of modulating tyrosine kinases, compositions comprising the compounds and methods of their use.

US Patent:

20130053376, Feb 28, 2013

Filed:

Mar 18, 2009

Appl. No.:

12/922891

Inventors:

Yahua Liu - San Diego CA, US
Alexey Vyacheslavovich Anikin - Ivanteevka, RU
Charles Chamchoumis Mikel - Esondido CA, US
Douglas Eric McGrath - Carlsbad CA, US
Goverdhan Reddy Vavilala - Morrisville NC, US
Jason Conrad Pickens - Chula Vista CA, US
Aleksander Kadushkin - Zheleznodorozhnyi, RU
Luyong Jiang - San Marcos CA, US
Mohan Santhanam Thiruvazhi - San Diego CA, US
Sergey Zozulya - Shrewsbury, RU
Rajendran Vairagoundar - Portage MI, US
Tong Zhu - San Diego CA, US
Alexander Chucholowski - San Diego CA, US
Zheng Yan - San Diego CA, US
Alisher Khasanov - Escondido CA, US
Christina Gregor - Del Mar CA, US

International Classification:

A61K 31/4545
C07D 401/14
A61K 31/4439
C07D 413/14
C12N 9/99
A61K 31/541
C07D 405/14
A61K 31/5377
A61P 35/00
C07D 487/04
C07D 417/14

US Classification:

5142285, 546194, 514318, 5462731, 514338, 5462721, 544 582, 544131, 5142328, 435184

Abstract:

Provided are compounds of the formula (I): or a stereoisomer, tautomer, salt, hydrate or prodrug thereof that modulate tyrosine kinase activity, compositions comprising the compounds and methods of their use.

US Patent:

20170224835, Aug 10, 2017

Filed:

Feb 5, 2016

Appl. No.:

15/017174

Inventors:

- San Diego CA, US
Gang Chen - San Diego CA, US
Tong Zhu - San Diego CA, US
Alisher B. Khasanov - San Diego CA, US
Dylan Deng - San Diego CA, US
Hong Zhang - San Diego CA, US
Zheng Yan - San Diego CA, US

Assignee:

Sorrento Therapeutics, Inc. - San Diego CA

International Classification:

A61K 47/48
A61K 31/65

Abstract:

There is disclosed antibody drug conjugates having anthracycline derivative drug moieties that provide improved safety and cell killing efficacy, wherein the anthracycline derivative drug moieties substitute an hydroxymethyl ketone moiety for an hydrazide or hydroxamate moiety. The disclosed cytotoxic agents (i.e., drug moieties) are conjugated to an antibody via either a Cys or a Lys residue. For Lys conjugation, the DAR (drug antibody ratio) of the majority of the ADC is 2 whereas the DAR of the majority of ADC is 4 when conjugation occurs on a Cys residue.